Lecanemab Accepted for US Review, Action Date Set for January: Eisai/Biogen

The US FDA has accepted for priority review Eisai’s application for its Alzheimer’s drug lecanemab under its accelerated pathway, the company and US partner Biogen said. An action date under the Prescription Drug User Fee Act (PDUFA) was set for...read more